Chronic myeloid leukaemia News and Research

RSS

Comorbidities relevant to CML TKI choice common

Comorbid conditions that could affect the choice of tyrosine kinase inhibitor are common in patients with chronic myeloid leukaemia, finds an analysis of a US claims database.

27 Nov 2015

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Four-year results for an ongoing study of second-line bosutinib indicate that the tyrosine kinase inhibitor offers long-term efficacy with manageable side effects for patients with chronic phase chronic myeloid leukaemia.

27 Nov 2015

CML arterial adverse events rate dependent on TKI choice

The risk of major arterial adverse events in chronic myeloid leukaemia patients may significantly differ between tyrosine kinase inhibitors, suggests a meta-analysis published in Leukemia & Lymphoma.

22 Oct 2015

CV risk assessment essential for CML TKI trial design

The risk and impact of cardiovascular adverse events in long-term users of tyrosine kinase inhibitors for chronic myeloid leukaemia is highlighted in a review published in the Journal of Clinical Oncology.

22 Oct 2015

‘Dismal prognosis’ of blast-phase CML patients highlighted

A team of Mexican researchers reports on the poor outcomes of a large series of Mexican patients with chronic myeloid leukaemia in blast phase.

22 Oct 2015

HLA-DPB1 regulatory region genotype predicts acute GVHD

Analysis of a HLA-DPB1 regulatory region variant has shed light on the risk of acute graft-versus-host disease in patients undergoing haematopoietic cell transplantation from an unrelated donor.

1 Oct 2015

Chromosome 3q26.2 rearrangements linked to poor CML prognosis

Rearrangements of chromosome 3q26.2 have a significant negative impact on patients with chronic myeloid leukaemia, suggests research published in Blood.

1 Oct 2015

Beta-catenin shows treatment target potential for TKI-resistant CML

Nuclear β-catenin could be a treatment target for patients whose chronic myeloid leukaemia is resistant to tyrosine kinase inhibitors independent of additional BCR–BL1 mutations, US researchers suggest.

1 Oct 2015

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Comparisons of cancer patients' survival and care in Europe up to 2007 show that although more patients are surviving for at least five years after diagnosis, there are large variations between countries, which are particularly significant in cancers of the blood.

26 Sep 2015

CML survey reveals patient TKI adherence, disease anxiety

Survey results suggest that chronic myeloid leukaemia patients using tyrosine kinase inhibitor therapy have good adherence to treatment but might benefit from counselling regarding their illness.

17 Aug 2015

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

Allogeneic haematopoietic stem cell transplantation can be considered for chronic- and accelerated-phase chronic myeloid leukaemia patients with prior exposure to second-generation tyrosine kinase inhibitors, say Polish researchers.

17 Aug 2015

TKI outcomes ‘unfavourable’ in young CML patients

Adolescent and young adult patients with chronic myeloid leukaemia may have an unfavourable outcome on tyrosine kinase inhibitor therapy compared with their older counterparts, suggests a study of Japanese patients.

17 Aug 2015

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

14 Aug 2015

CML survey reveals patient TKI adherence, disease anxiety

Survey results suggest that chronic myeloid leukaemia patients using tyrosine kinase inhibitor therapy have good adherence to treatment but might benefit from counselling regarding their illness.

14 Aug 2015

TKI outcomes ‘unfavourable’ in young CML patients

14 Aug 2015

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.

7 Aug 2015

Hedgehog blockade promising in myeloid malignancies

Phase I trial results published in The Lancet Haematology show that the hedgehog signalling pathway antagonist PF-04449913 is tolerable and has activity in patients with haematological cancers.

5 Aug 2015

Bosutinib resistance linked to ABCB1 transporter

Resistance to the tyrosine kinase inhibitor bosutinib may be mediated by overexpression of the efflux transporter ABCB1, scientists suggest.

24 Jul 2015

Rare BCR-ABL fusions highlighted in CML

Chronic myeloid leukaemia patients with rare BCR-ABL fusions may be missed by quantitative polymerase chain reaction, research suggests.

24 Jul 2015

Patient characteristics may guide TKI use in CML

The likelihood of complications associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia may be reduced by considering patient factors and differences in the toxicity profiles of the different drug options, a review suggests.

29 May 2015